CHICAGO, Aug. 13, 2018 /PRNewswire/ -- Opternative, Inc. is pleased to report that it secured a major victory in its
On August 7, 2018, the Court denied Warby's motion to dismiss Opternative's claim for breach of the numerous non-disclosure agreements entered into between the parties, finding that:
Opternative alleges Warby Parker used Opternative's Confidential Information—including demonstrations of its in-development system, internal memoranda and reports, and methods of distance determination using a camera—to inform its decision to enter the online refraction market, in making strategic and marketing decisions, in the invention of the 709 Patent, and in the design and development of Prescription Check. These allegations are sufficient to establish circumstantial evidence from which the factfinder could infer that Warby Parker used Opternative's Confidential Information for purposes other than evaluating a business relationship with Opternative, in breach of the NDAs.
Opternative, Inc. v. JAND, Inc. (d/b/a Warby Parker), 17-cv-6936-JFK, Dkt. 42 at 17 (S.D.N.Y. Aug. 7, 2018). This comes less than two weeks following oral argument on Warby's motion to dismiss before the United States District Court for the Southern District of New York. While the Court dismissed Opternative's trade secret claims, it provided Opternative an opportunity to amend its complaint as to those counts.
"We are confident that our litigation against Warby will lead to success for Opternative," said Opternative's CEO, Brent Rasmussen. "We look forward to continuing discovery and achieving a positive outcome."
About OpternativeOpternative Inc., a Chicago-based healthcare technology company, founded in 2012, creates digital eye care technologies that enable patient choice and convenience while providing doctors and retailers the ability to create awesome user experiences. Opternative has created the most convenient and scientifically accurate digital refractive vision test.
Opternative partners can now offer their clients a refractive vision test and acuity screenings from anywhere at any time. Opternative has partnered with eye care providers and eyewear retailers across the U.S. to bring this revolutionary service to our partners' clients. For more information on partnering with Opternative, email BD@Opternative.com or visit our partner page here.
Media Contact:Shelby Eversoleshelby.email@example.com
View original content:http://www.prnewswire.com/news-releases/opternative-wins-in-first-round-of-ongoing-litigation-with-warby-parker-300695822.html
SOURCE Opternative, Inc.
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All